Literature DB >> 29779179

Clinical outcomes of complete revascularization using either angiography-guided or fractional flow reserve-guided drug-eluting stent implantation in non-culprit vessels in ST elevation myocardial infarction patients: insights from a study based on a systematic review and meta-analysis.

Alexandre Hideo-Kajita1, Hector M Garcia-Garcia2, Kayode O Kuku1, Solomon S Beyene1, Viana Azizi1, Yael F Meirovich1, Gebremedhin D Melaku1, Aaphtaab Dheendsa1, Echo J Brathwaite1, Sameer Desale1, Mohammad Soud1, Kazuhiro Dan1, Yuichi Ozaki1, Ron Waksman1, Michael Lipinski1.   

Abstract

Current guidelines recommend that percutaneous coronary intervention (PCI) should be restricted to the culprit vessel in ST elevation myocardial infarction (STEMI) patients with multi-vessel disease (MVD) and without cardiogenic shock. However, newer data suggests that performing complete revascularization (CR) in MVD patients may lead to better outcomes compared to intervention in the culprit vessel only. The aim of this meta-analysis is to examine the available data to determine if CR (using either angio- or fractional flow reserve guidance-FFR) following primary PCI in STEMI patients without cardiogenic shock impacts clinical outcomes. Meta-analysis was performed by conducting a literature search of PubMed from January 2004 to July 2017. Pooled estimates of outcomes, presented as odds ratios (OR) [95% confidence intervals], were generated using random-effect models. A total of 9 studies (3317 patients) were included. CR showed a significant MACE reduction (OR 0.49, 95% CI 0.36-0.66, p < 0.001); All-cause mortality (OR 0.69, 95% CI 0.48-0.98, p = 0.04) and repeat revascularization (OR 0.38, 95% CI 0.28-0.51, p < 0.001) at ≥ 12 months follow-up. The FFR-guiding CR group presented a MACE reduction (odds ratio 0.52, 95% CI 0.30-0.90, p = 0.02) due to a decrease of repeat revascularization (OR 0.41, 95% CI 0.21-0.80, p = 0.009). Overall, performing complete revascularization in STEMI patients showed a MACE reduction, all-cause death and repeat revascularization. Compared to culprit-only revascularization, treating multi-vessel disease in STEMI patients using FFR guidance is associated with decreased incidence of MACE, due to a decreased rate of revascularization.

Entities:  

Keywords:  Drug-eluting stent; Fractional flow reserve; Meta-analysis; STEMI complete revascularization; Systematic review

Mesh:

Year:  2018        PMID: 29779179     DOI: 10.1007/s10554-018-1362-9

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  49 in total

1.  Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomised clinical trial.

Authors:  A Ghani; J-H E Dambrink; A W J van 't Hof; J P Ottervanger; A T M Gosselink; J C A Hoorntje
Journal:  Neth Heart J       Date:  2012-09       Impact factor: 2.380

2.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

3.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

4.  Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction.

Authors:  Pieter C Smits; Mohamed Abdel-Wahab; Franz-Josef Neumann; Bianca M Boxma-de Klerk; Ketil Lunde; Carl E Schotborgh; Zsolt Piroth; David Horak; Adrian Wlodarczak; Paul J Ong; Rainer Hambrecht; Oskar Angerås; Gert Richardt; Elmir Omerovic
Journal:  N Engl J Med       Date:  2017-03-18       Impact factor: 91.245

5.  Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms.

Authors:  J H Reiber; P W Serruys; C J Kooijman; W Wijns; C J Slager; J J Gerbrands; J C Schuurbiers; A den Boer; P G Hugenholtz
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690

6.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.

Authors:  Jonathan A C Sterne; Alex J Sutton; John P A Ioannidis; Norma Terrin; David R Jones; Joseph Lau; James Carpenter; Gerta Rücker; Roger M Harbord; Christopher H Schmid; Jennifer Tetzlaff; Jonathan J Deeks; Jaime Peters; Petra Macaskill; Guido Schwarzer; Sue Duval; Douglas G Altman; David Moher; Julian P T Higgins
Journal:  BMJ       Date:  2011-07-22

Review 7.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

8.  Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.

Authors:  Paul Sorajja; Bernard J Gersh; David A Cox; Michael G McLaughlin; Peter Zimetbaum; Costantino Costantini; Thomas Stuckey; James E Tcheng; Roxana Mehran; Alexandra J Lansky; Cindy L Grines; Gregg W Stone
Journal:  Eur Heart J       Date:  2007-06-07       Impact factor: 29.983

Review 9.  Optimal Timing of Complete Revascularization in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Rouan Gaffar; Bettina Habib; Kristian B Filion; Pauline Reynier; Mark J Eisenberg
Journal:  J Am Heart Assoc       Date:  2017-04-10       Impact factor: 5.501

10.  Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.

Authors:  Anthony H Gershlick; Jamal Nasir Khan; Damian J Kelly; John P Greenwood; Thiagarajah Sasikaran; Nick Curzen; Daniel J Blackman; Miles Dalby; Kathryn L Fairbrother; Winston Banya; Duolao Wang; Marcus Flather; Simon L Hetherington; Andrew D Kelion; Suneel Talwar; Mark Gunning; Roger Hall; Howard Swanton; Gerry P McCann
Journal:  J Am Coll Cardiol       Date:  2015-03-17       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.